HarrisonWFarberMD
Pulmonology • Boston, MACritical Care Medicine, Pleural Disease
Professor, Medicine, Boston University School of Medicine
Dr. Farber is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
725 Albany St
# Shapiro
Boston, MA 02118Phone+1 617-638-7480Fax+1 617-638-7486
Education & Training
Boston University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 1981 - 1984
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 1977 - 1980
George Washington University School of Medicine and Health SciencesClass of 1977
Certifications & Licensure
MA State Medical License 1981 - 2025
VA State Medical License 1978 - 2000- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2010-2013
- Elected Member The American Society for Clinical Investigation, 1992
- Top MD Consumers Checkbook
Clinical Trials
- REVEAL Registry™: Registry to Evaluate Early And Long-term PAH Disease Management Start of enrollment: 2006 Mar 01
- Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) Start of enrollment: 2011 Jun 24
- Selexipag (ACT-293987) in Pulmonary Arterial Hypertension Start of enrollment: 2009 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Risk Assessment Tools in Pulmonary Arterial Hypertension: Why Can't We Be Friends?Nicole F Ruopp, Harrison W Farber
Chest. 2024-11-01 - Mechanical Preload Reduction: Harnessing a Cornerstone of Heart Failure Management to Improve Clinical Outcomes.Navin K Kapur, Manreet K Kanwar, Rayan Yousefzai, Arvind Bhimiraj, Harrison Farber
ASAIO Journal. 2024-10-01 - Fucosylation: The Prognostic Impact of Sugar in Pulmonary Arterial Hypertension.Harrison W Farber, Noah C Schoenberg
Journal of the American College of Cardiology. 2024-09-17
Journal Articles
- Serum Biomarker for Diagnostic Evaluation of Pulmonary Arterial Hypertension in Systemic SclerosisHarrison W Farber, Kari Roberts, Nicholas Hill, Robyn Domsic, Robert W Simms, BioMed Central
Lectures
- 10th International Pulmonary Hypertension Conference and Scientific SessionsPulmonary Hypertension Association, Orlando, Florida - 6/22/2012
Other
- Pulmonary complications of sickle cell diseaseFarber HW, Hammerman SI
http://www.uptodate.com/contents/pulmonary-complications-of-sickle-cell-disease
UpToDate, Wolters Kluwer Health - 2012-11-05 - Foreign body granulomatosisFarber HW, Hendra KP
http://www.uptodate.com/contents/foreign-body-granulomatosis
UpToDate, Wolters Kluwer Health - 2012-05-11 - Pulmonary hypertension associated with human immunodeficiency virusFarber HW, Ieong M
http://www.uptodate.com/contents/pulmonary-hypertension-associated-with-human-immunodeficiency-virus
UpToDate, Wolters Kluwer Health - 2012-09-06
Press Mentions
Pulmonary Arterial HypertensionJune 28th, 2016
Grant Support
- Biomarkers Of Pulmonary Complications Of Scleroderma: The Ssc-Pah AndNational Institute Of Arthritis And Musculoskeletal And Skin Diseases2011
- Oxidant State And Nitric Oxide Metabolism In The Acute Chest SyndromeNational Heart, Lung, And Blood Institute2004–2007
- Endothelial Cell Hypoxia Tolerance: Role Of PlasmalogensNational Heart, Lung, And Blood Institute2003–2006
- Endothelial Cell Hypoxia Associated ProteinsNational Heart, Lung, And Blood Institute1997–2000
- Endothelial Cell Hypoxia-Associated ProteinsNational Heart, Lung, And Blood Institute1993–1996
- Endothelial Cell Derived Neutrophil ChemoattractantsNational Heart, Lung, And Blood Institute1985–1987
Other Languages
- French
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
